FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:208-209 July 9, 2009 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kramer, J. M. Related Article by Drazen, J. M. PubMed Citation

To the Editor: In her Perspective article, Kramer (April 16 issue)¹ succinctly summarizes the decisions of the Food and Drug Administration (FDA) regarding the continued availability of single-agent long-acting beta-agonist (LABA) inhalers for use in patients with asthma. She further clarifies that these drugs would remain on the market for patients with chronic obstructive pulmonary disease (COPD), even if the asthma indication were removed.

As a practicing pulmonary physician, I have a different perspective to offer for debate. A not insignificant number of patients that my colleagues and I see do not correctly differentiate between asthma and COPD, and therefore, . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.